SCHEMBL608911

SCHEMBL608911

NC(=O)CCCC(=O)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 12/20 0.66
HDAC1 Q13547 12/20 0.66
HDAC7 Q8WUI4 12/20 0.66
HDAC11 Q96DB2 12/20 0.66
HDAC8 Q9BY41 12/20 0.66
HDAC6 Q9UBN7 12/20 0.66
HDAC9 Q9UKV0 12/20 0.66
HDAC5 Q9UQL6 12/20 0.66
HDAC3 O15379 11/20 0.66
HDAC2 Q92769 11/20 0.66
HDAC10 Q969S8 11/20 0.66
CYP3A4 P08684 3/20 0.66
NCOR2 Q9Y618 2/20 0.66
KCNH2 Q12809 2/20 0.66
NCOR1 O75376 2/20 0.66
KDM4E B2RXH2 1/20 0.66
BRD4 O60885 1/20 0.66
NR1I2 O75469 1/20 0.66
EGFR P00533 1/20 0.66
LTA4H P09960 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10497217 0.96 HDAC6 (0.71) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1065527 0.94 HDAC6 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1433994 0.94 HDAC6 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL6296181 0.92 HDAC4 (0.75) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL3353284 0.90 L3MBTL1 (0.72) HDAC4HDAC1HDAC7HDAC11HDAC8
Trifluoroacetic Acid SCHEMBL3202548 0.90 HDAC4 (0.66) HDAC4HDAC1HDAC7HDAC11HDAC8
Hydrochloric Acid SCHEMBL3353961 0.89 L3MBTL1 (0.70) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL517309 0.88 HDAC4 (0.81) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL29266758 0.87 SOAT2 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL3806017 0.86 MEN1 (0.73) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106000465-A Method for oxidative coupling reaction of aldehyde and secondary amide 苏州大学 2016-10-12 CN claimed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
JP-2004502669-A 2004-01-29 JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed
EP-0666848-B1 SUBSTITUTED N-PHENYLGLUTARIMIDES AND N-PHENYLGLUTARIC ACID AMIDES, THEIR PREPARATION AND USE IN AGRICULTURE BASF AG (DE) 1998-12-30 EP claimed
US-5698494-A Substituted N-phenylglutarimides and N-phenylglutaramides, their preparation and use BASF AKTIENGESELLSCHAFT (DE) 1997-12-16 US claimed
EP-0666848-A1 SUBSTITUTED N-PHENYLGLUTARIMIDES AND N-PHENYLGLUTARIC ACID AMIDES, THEIR PREPARATION AND USE IN AGRICULTURE BASF Aktiengesellschaft (DE) 1995-08-16 EP claimed
WO-1994010147-A1 SUBSTITUTED N-PHENYLGLUTARIMIDES AND N-PHENYLGLUTARIC ACID AMIDES, THEIR PREPARATION AND USE IN AGRICULTURE BASF AKTIENGESELLSCHAFT (DE) 1994-05-11 WO claimed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 EP disclosed
EP-0666848-A1 SUBSTITUTED N-PHENYLGLUTARIMIDES AND N-PHENYLGLUTARIC ACID AMIDES, THEIR PREPARATION AND USE IN AGRICULTURE BASF Aktiengesellschaft (DE) 1995-08-16 EP disclosed
WO-1994010147-A1 SUBSTITUTED N-PHENYLGLUTARIMIDES AND N-PHENYLGLUTARIC ACID AMIDES, THEIR PREPARATION AND USE IN AGRICULTURE BASF AKTIENGESELLSCHAFT (DE) 1994-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 HDAC4 271/4885HDAC1 249/4885HDAC7 275/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 HDAC4 271/4885HDAC1 249/4885HDAC7 275/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 HDAC4 271/4885HDAC1 249/4885HDAC7 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.